News and Trends 24 Feb 2025 Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree? …but this time around, for the chronic respiratory illness idiopathic pulmonary fibrosis (IPF). The candidate MTX-463 is a human IgG1 antibody designed to neutralize WISP1-mediated fibrotic signaling in IPF. The… February 24, 2025 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2020 Swedish Biotech’s Psoriasis Drug Beats Placebo in Phase II …the market such as Humira and Cosentyx, these antibody drugs aren’t well suited to subcutaneous injections because they can’t penetrate subcutaneous tissue well. Affibody’s psoriasis candidate is a protein drug… June 22, 2020 - 3 minutesmins - By David Wilson Share WhatsApp Twitter Linkedin Email
News and Trends 14 Feb 2018 Bicycle’s First Peptide-Toxin Conjugate Enters the Clinic for Solid Tumors …has dosed the first patient in a Phase I/IIa trial with its solid tumors candidate, BT1718. The study will test the drug’s safety and efficacy in around 120 patients with… February 14, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
In Depth 28 Jul 2022 How can vaccines keep up with evolving Covid-19 variants? …the spike antigen becomes. This makes the key target of the antibody response more subject to mutations,” said Alexandre Le Vert, executive chairman and co-founder of the French vaccine firm… July 28, 2022 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 May 2019 Belgian Biotech Raises €30M Series A to Unlock Undruggable Targets …led by the VCs BioGeneration Ventures and Wellington Partners, and joined by several other private and public investors. With the money, Confo Therapeutics aims to test its first drug candidate… May 7, 2019 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 3 Dec 2025 Greener pastures for biopharma? Biotechs in Ireland causing a stir …past five years and are going strong. Table of contents SynOx Therapeutics Founded: 2020 Focus: Monoclonal antibody for tenosynovial giant cell tumor Headquartered in Ireland, biotech company SynOx Therapeutics focuses its R&D on treating tenosynovial giant cell tumor, a rare… December 3, 2025 - 11 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 27 Nov 2018 Berlin Biotech Raises €24M to Progress Septic Shock Candidate to Clinic Adrenomed closed a €24M Series D round to fund further development of its antibody drug that treats septic shock by preventing excessive fluid loss and preserving the blood vessel walls…. November 27, 2018 - 3 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 21 Nov 2024 Huntington’s disease: a therapeutic field on a bumpy ride …in 2022 upon demanding more dosage data. Prilenia’s Huntington’s candidate pridopidine accepted for EMA review Meanwhile, Dutch biotech Prilenia Therapeutics’ Huntington’s candidate is en route to approval. Two weeks ago,… November 21, 2024 - 9 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 11 Oct 2022 License granted to EnteroBiotix for manufacture of microbiome product candidates Microbiome therapeutics company, EnteroBiotix Limited has been granted a manufacturer’s license for a GMP manufacturing facility for Investigational Medicinal Products (IMP) to make microbiome product candidates for clinical trials. It… October 11, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 5 Oct 2022 FDA fast tracks Immutep non-small cell lung cancer candidate …first line non-small cell lung cancer (NSCLC). Efti is the company’s first-in-class soluble LAG-3 clinical stage candidate, which activates antigen presenting cells (APC) to engage both the innate and adaptive… October 5, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 29 Nov 2023 Redefining drug development: the trailblazing evolution of the pharmaceutical industry …after drug candidates are rigorously optimized at the preclinical stage. However, nine out of ten drug candidates would fail during phase 1, 2, 3 clinical trials and drug approval. It… November 29, 2023 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 20 Oct 2022 Alvotech and JAMP Pharma add two biosimilar candidates for Canadian market Alvotech and the JAMP Pharma Group have expanded their exclusive partnership to commercialize biosimilars developed and manufactured by Alvotech. The companies have added two biosimilar candidates from Alvotech’s pipeline: AVT16,… October 20, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email